Nomogram helps predict biochemical failure risk post RP
The Kattan biochemical recurrence-free progression nomogram helps predict biochemical failure risk at 5 and 10 years in men who have had radical prostatectomy, according to a recent study.
Use of the nomogram, along with other factors, such as PSA level and family history, is a reliable, useful tool for helping urologists and their patients make better treatment decisions, the study’s lead author tells Urology Times.
Rochelle Payne Ondracek, PhD, of Roswell Park Cancer Institute, New York, led a study, published in the Journal of the National Comprehensive Cancer Network (2016; 14:1395-401), to validate the Kattan nomogram for prostate cancer recurrence after radical prostatectomy. Among the study’s authors are the nomogram’s developer, Michael W. Kattan, MBA, PhD, of Cleveland Clinic.
“Dr. Kattan has been developing nomograms for a variety of diseases and treatments. We were particularly interested in the post radical prostatectomy because we had a large group of patients with very detailed outcomes. We compared the predicted Kattan nomogram outcomes with the actual outcomes,” Dr. Ondracek said.
Recommended: Upbringing, socioeconomic status linked to PCa
The nomogram predicts probability for disease-free survival on a scale from 0% to 100%. To study it, the authors looked at data from 1,931 men who had radical prostatectomy performed at Roswell Park Cancer Institute between 1993 and 2014. The patients had been assessed for National Comprehensive Cancer Network-defined biochemical failure and Roswell Park Cancer Institute-defined treatment failure.